Guggenheim Maintains Buy on Natera, Raises Price Target to $475

10/1/2026
Impact: 85
Healthcare

Guggenheim analyst Subbu Nambi has maintained a Buy rating on Natera (NASDAQ: NTRA) and raised the price target from $360 to $475. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: